Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Rheumatology

What Are the McAdam, Damiani-Levine, and Michet Criteria?

At a Glance

The McAdam, Damiani-Levine, and Michet criteria are clinical checklists—not definitive tests—for recognizing relapsing polychondritis. They use different combinations of cartilage symptoms, other clinical findings, and sometimes biopsy, so not meeting one checklist does not rule out early disease.

When doctors suspect relapsing polychondritis (RP), they often refer to the McAdam, Damiani-Levine, or Michet criteria. These are not definitive blood tests or imaging scans. Instead, they are classification and diagnostic aids—essentially clinical checklists—used to help recognize the disease pattern [1] [2]. Because no single laboratory test can prove you have RP, these three systems were developed to help doctors identify the characteristic combinations of inflamed cartilage and other affected tissues [2]. It is important to know that these criteria were largely designed to group patients for research; in the clinic, your doctor can diagnose and treat you even if you don’t perfectly match a checklist [2] [3].

What Do the Different Systems Measure?

While all three systems look for the classic signs of RP, they require different combinations of symptoms or test results:

  • McAdam Criteria: This original system focuses on six specific clinical manifestations: recurrent or bilateral inflammation of the ear cartilage (auricular chondritis), nasal cartilage inflammation, non-erosive joint inflammation (polyarthritis), eye inflammation, respiratory tract cartilage inflammation, and inner ear issues (cochlear or vestibular dysfunction) [1] [4] [5]. To satisfy the McAdam criteria, a patient must have at least three of these six features [4] [5].
  • Damiani-Levine Criteria: This system broadened the criteria to make it easier to classify RP when fewer symptoms are present, provided there is other supportive evidence. Under the Damiani-Levine system, a patient may satisfy the criteria if they have just one or more of the classic clinical features in conjunction with a confirming cartilage biopsy [6] [7].
  • Michet Criteria: This system is another clinical framework that organizes symptoms into major and minor categories, requiring specific combinations of clinical features to meet its threshold [7] [6].

Comparison of Frameworks (Supportive Aids, Not Pass/Fail Tests)

System Primary Approach Role of Biopsy Limitation
McAdam Requires 3 of 6 classic clinical features [4] [5]. Not explicitly required to meet the 3-feature threshold [1]. Often misses early or limited disease [3].
Damiani-Levine Broadens McAdam; allows fewer symptoms if tissue evidence is present [6]. A core pathway allows diagnosis with 1+ clinical feature plus biopsy [6]. Biopsy can be invasive and a negative result doesn’t rule out RP [8].
Michet Uses a combination of major and minor clinical features [7]. Clinical diagnosis framework; biopsy is not the primary requirement [7]. Studies show varied sensitivity depending on if original or modified versions are used [7].

The Role (and Limits) of Cartilage Biopsy

A biopsy (taking a small sample of cartilage to examine under a microscope) is not always required to diagnose RP, especially if you have multiple clear clinical symptoms [1] [6]. However, in the Damiani-Levine framework, a biopsy plays a central role by corroborating the clinical suspicion when only one symptom is present [6].

If a biopsy is considered, the ear (auricle) is often a preferred, accessible site [8]. Studies in specific patient groups show that ear biopsies can successfully identify inflammatory cells and cartilage damage, sometimes even when the ear is currently asymptomatic [8] [9]. In contrast, biopsies of the airway (trachea or bronchi) are less likely to provide a definitive result and carry higher risks [8].

However, a biopsy is not a routine, harmless procedure. It can cause pain, bleeding, infection, scarring, or permanent cosmetic deformity to the ear. Most importantly, a normal biopsy does not rule out RP, and finding inflammation does not prove RP by itself [2]. The decision to biopsy should be weighed carefully with a specialist to determine if it will actually change your treatment plan.

Why Clinicians Might Reach Different Conclusions

It is common for the diagnosis to remain uncertain early on. If one doctor says you meet the criteria for RP and another says you do not, it usually stems from:

  • Differing Thresholds: The systems have different requirements. In a small 18-patient study, the criteria successfully identified the disease (sensitivity) in anywhere from 50% to roughly 89% of confirmed cases, depending on which exact rules were applied [7].
  • Early or Partial Disease: These checklists were based on patients with classic, fully developed RP. In one study of 87 clinically diagnosed patients, 65.5% did not meet the Michet or Damiani thresholds because they had “partial” or “limited” disease [3]. Cartilage inflammation can take years to fully appear [2] [3]. Not meeting a checklist does not mean your symptoms aren’t real.
  • Conditions That Resemble RP: Doctors must carefully rule out conditions that overlap with or resemble RP [2]. A major one is VEXAS syndrome, an acquired (not inherited) condition caused by a genetic mutation (UBA1) in blood cells, often seen in older men. VEXAS can cause fevers, skin/lung issues, and abnormal blood counts that overlap with RP [10] [11]. Other mimics include granulomatosis with polyangiitis (GPA, a type of blood vessel inflammation), infections, and side effects from certain cancer immunotherapies [12] [13].

Urgent Warning: Because RP can weaken or narrow the airway, any new or worsening shortness of breath, noisy breathing (stridor), hoarseness, or trouble swallowing requires urgent medical assessment. Do not wait for a routine appointment. Sudden severe eye pain, vision changes, or sudden hearing loss and vertigo also require prompt specialist care.

Common questions in this guide

What are the McAdam criteria for relapsing polychondritis?
The McAdam criteria look for six features: ear cartilage inflammation, nose cartilage inflammation, non-erosive joint inflammation, eye inflammation, respiratory tract cartilage inflammation, and inner-ear problems affecting hearing or balance. A person meets this checklist when at least three are present. It is a clinical aid, not a definitive blood test, and it may miss early or limited disease.
How are the Damiani-Levine and Michet criteria different?
Damiani-Levine broadens the original approach by allowing fewer classic features when a cartilage biopsy provides supporting evidence. Michet uses combinations of major and minor clinical features rather than a simple three-feature rule. Both are aids for organizing the diagnosis, and their performance can vary.
Do I need a cartilage biopsy to diagnose relapsing polychondritis?
Not always. A biopsy may help when only a small number of symptoms are present, but many people can be assessed from a clear pattern of clinical findings. Biopsy can cause pain, bleeding, infection, scarring, or ear deformity, and a normal result does not rule out relapsing polychondritis.
Can I have relapsing polychondritis if I do not meet a diagnostic checklist?
Yes. These criteria were largely created to group patients for research, and early or limited relapsing polychondritis may not show enough features to meet a particular checklist. A clinician can continue evaluating symptoms over time and use the overall clinical picture rather than treating one checklist as a pass-or-fail test.
What other conditions can resemble relapsing polychondritis?
Doctors may consider VEXAS syndrome, granulomatosis with polyangiitis, infections, and reactions to some cancer immunotherapies. VEXAS is an acquired condition involving a UBA1 mutation in blood cells and can cause symptoms that overlap with relapsing polychondritis. Testing for look-alike conditions may help clarify the diagnosis.
Which symptoms need urgent medical attention if I may have relapsing polychondritis?
New or worsening shortness of breath, noisy breathing, hoarseness, or trouble swallowing can signal airway involvement and requires urgent assessment. Sudden severe eye pain, vision changes, sudden hearing loss, or vertigo also need prompt specialist care. Do not wait for a routine appointment when these symptoms occur.

Get notified when new evidence is published on Relapsing polychondritis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    Relapsing Polychondritis: An Updated Review.

    Borgia F, Giuffrida R, Guarneri F, Cannavò SP

    Biomedicines 2018; (6(3)) doi:10.3390/biomedicines6030084.

    PMID: 30072598
  2. 2

    French practical guidelines for the diagnosis and management of relapsing polychondritis.

    Arnaud L, Costedoat-Chalumeau N, Mathian A, et al.

    La Revue de medecine interne 2023; (44(6)):282-294 doi:10.1016/j.revmed.2023.05.005.

    PMID: 37236870
  3. 3

    Diagnosing relapsing polychondritis remains a common challenge: experience from a Chinese retrospective cohort.

    Zhang L, Wu TG, He YJ, et al.

    Clinical rheumatology 2020; (39(7)):2179-2184 doi:10.1007/s10067-019-04852-3.

    PMID: 32036586
  4. 4

    Relapsing polychondritis: a clinical review for rheumatologists.

    Kingdon J, Roscamp J, Sangle S, D'Cruz D

    Rheumatology (Oxford, England) 2018; (57(9)):1525-1532 doi:10.1093/rheumatology/kex406.

    PMID: 29126262
  5. 5

    Coexistence of Relapsing Polychondritis and Sickle Cell Disease in a Child.

    Tetteh BO, Yebuah FB, Amissah-Arthur MB, Dey D

    Case reports in rheumatology 2021; (2021()):3600451 doi:10.1155/2021/3600451.

    PMID: 34868694
  6. 6

    Relapsing polychondritis: A clinical update.

    Longo L, Greco A, Rea A, et al.

    Autoimmunity reviews 2016; (15(6)):539-43.

    PMID: 26876384
  7. 7

    Observational study and brief analysis of diagnostic criteria in relapsing polychondritis.

    Rose T, Schneider U, Bertolo M, et al.

    Rheumatology international 2018; (38(11)):2095-2101 doi:10.1007/s00296-018-4121-2.

    PMID: 30084004
  8. 8

    Is 18F-FDG PET/CT useful for diagnosing relapsing polychondritis with airway involvement and monitoring response to steroid-based therapy?

    Zeng Y, Li M, Chen S, et al.

    Arthritis research & therapy 2019; (21(1)):282 doi:10.1186/s13075-019-2083-8.

    PMID: 31831053
  9. 9

    FDG-PET/CT and Auricular Cartilage Biopsy Are Useful for Diagnosing with Relapsing Polychondritis in Patients without Auricular Symptoms.

    Okuda S, Hirooka Y, Itami T, et al.

    Life (Basel, Switzerland) 2021; (11(9)) doi:10.3390/life11090956.

    PMID: 34575105
  10. 10

    Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS.

    Ferrada MA, Sikora KA, Luo Y, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2021; (73(10)):1886-1895 doi:10.1002/art.41743.

    PMID: 33779074
  11. 11

    Relapsing polychondritis: clinical updates and new differential diagnoses.

    Mertz P, Costedoat-Chalumeau N, Ferrada MA, et al.

    Nature reviews. Rheumatology 2024; (20(6)):347-360 doi:10.1038/s41584-024-01113-9.

    PMID: 38698240
  12. 12

    [Restatement. Relapsing polychondritis].

    Mertz P, Arnaud L

    La Revue du praticien 2023; (73(5)):549-556.

    PMID: 37309797
  13. 13

    Differentiating tracheobronchial involvement in granulomatosis with polyangiitis and relapsing polychondritis on chest CT: a cohort study.

    Jalaber C, Puéchal X, Saab I, et al.

    Arthritis research & therapy 2022; (24(1)):241 doi:10.1186/s13075-022-02935-2.

    PMID: 36307863

This page is for informational purposes only and does not constitute medical advice. It explains relapsing polychondritis diagnostic criteria and biopsy considerations; your rheumatologist should interpret your symptoms and test results.